{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T10:06:48Z","timestamp":1790676408449,"version":"4.1.0"},"reference-count":82,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,2,13]],"date-time":"2023-02-13T00:00:00Z","timestamp":1676246400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>The pervasive human cytomegalovirus (HCMV) causes significant morbidity in immunocompromised individuals. Treatment using the current standard-of-care (SOC) is limited by severe toxic adverse effects and anti-viral resistance development. Furthermore, they only affect HCMV in its lytic phase, meaning viral disease is not preventable as latent infection cannot be treated and the viral reservoirs persist. The viral chemokine receptor (vCKR) US28 encoded by HCMV has received much attention in recent years. This broad-spectrum receptor has proven to be a desirable target for development of novel therapeutics through exploitation of its ability to internalize and its role in maintaining latency. Importantly, it is expressed on the surface of infected cells during both lytic and latent infection. US28-targeting small molecules, single-domain antibodies, and fusion toxin proteins have been developed for different treatment strategies, e.g. forcing reactivation of latent virus or using internalization of US28 as a toxin shuttle to kill infected cells. These strategies show promise for providing ways to eliminate latent viral reservoirs and prevent HCMV disease in vulnerable patients. Here, we discuss the progress and challenges of targeting US28 to treat HCMV infection and its associated diseases.<\/jats:p>","DOI":"10.3389\/fimmu.2023.1135280","type":"journal-article","created":{"date-parts":[[2023,2,13]],"date-time":"2023-02-13T06:56:50Z","timestamp":1676271410000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":12,"title":["Therapeutic targeting of HCMV-encoded chemokine receptor US28: Progress and challenges"],"prefix":"10.3389","volume":"14","author":[{"given":"Christian","family":"Berg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mette M.","family":"Rosenkilde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,2,13]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-virology-100220-113942","article-title":"Viral G protein-coupled receptors encoded by beta- and gamma-herpesviruses","volume":"9","author":"Rosenkilde","year":"2022","journal-title":"Annu Rev Virol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1159\/000492161","article-title":"Chemokine subversion by human herpesviruses","volume":"10","author":"Pontejo","year":"2018","journal-title":"J Innate Immun"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1002\/rmv.2034","article-title":"Estimation of the worldwide seroprevalence of cytomegalovirus: A systematic review and meta-analysis","volume":"29","author":"Zuhair","year":"2019","journal-title":"Rev Med Virol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pcbi.1005719","article-title":"Infectious reactivation of cytomegalovirus explaining age- and sex-specific patterns of seroprevalence","volume":"13","author":"van Boven","year":"2017","journal-title":"PloS Comput Biol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1002\/path.4437","article-title":"The pathogenesis of human cytomegalovirus","volume":"235","author":"Griffiths","year":"2015","journal-title":"J Pathol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1002\/rmv.535","article-title":"Review and meta-analysis of the epidemiology of congenital cytomegalovirus (Cmv) infection","volume":"17","author":"Kenneson","year":"2007","journal-title":"Rev Med Virol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1128\/CMR.00062-12","article-title":"The \"Silent\" global burden of congenital cytomegalovirus","volume":"26","author":"Manicklal","year":"2013","journal-title":"Clin Microbiol Rev"},{"key":"B8","volume-title":"Vaccines for the 21st century : A tool for decisionmaking","author":"Stratton","year":"2000"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/12.supplement_7.s754","article-title":"Impact of cytomegalovirus infection on organ transplant recipients","author":"Rubin","year":"1990","journal-title":"Rev Infect Dis"},{"key":"B10","article-title":"Human cytomegalovirus infection and expression in human malignant glioma","volume":"62","author":"Cobbs","year":"2002","journal-title":"Cancer Res"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1215\/15228517-2007-035","article-title":"Sensitive detection of human cytomegalovirus in tumors and peripheral blood of patients diagnosed with glioblastoma","volume":"10","author":"Mitchell","year":"2008","journal-title":"Neuro Oncol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/s00401-008-0359-1","article-title":"Detection of human cytomegalovirus in different histological types of gliomas","volume":"116","author":"Scheurer","year":"2008","journal-title":"Acta Neuropathol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1007\/978-3-540-77349-8_22","article-title":"Mechanisms of cytomegalovirus-accelerated vascular disease: Induction of paracrine factors that promote angiogenesis and wound healing","volume":"325","author":"Streblow","year":"2008","journal-title":"Curr Top Microbiol Immunol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.116.005025","article-title":"Cytomegalovirus infection and relative risk of cardiovascular disease (Ischemic heart disease, stroke, and cardiovascular death): A meta-analysis of prospective studies up to 2016","volume":"6","author":"Wang","year":"2017","journal-title":"J Am Heart Assoc"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/s41579-021-00582-z","article-title":"Pathogenesis of human cytomegalovirus in the immunocompromised host","volume":"19","author":"Griffiths","year":"2021","journal-title":"Nat Rev Microbiol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.coph.2008.07.002","article-title":"Antiviral strategies to combat cytomegalovirus infections in transplant recipients","volume":"8","author":"Lischka","year":"2008","journal-title":"Curr Opin Pharmacol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-017-0860-8","article-title":"Letermovir: First global approval","volume":"78","author":"Kim","year":"2018","journal-title":"Drugs"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2020.00130","article-title":"Cytomegalovirus latency and reactivation: An intricate interplay with the host immune response","volume":"10","author":"Forte","year":"2020","journal-title":"Front Cell Infect Microbiol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1093\/bmb\/ldz031","article-title":"Advances in the treatment of cytomegalovirus","volume":"131","author":"Krishna","year":"2019","journal-title":"Br Med Bull"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3390\/v13050817","article-title":"Hcmv antivirals and strategies to target the latent reservoir","volume":"13","author":"Perera","year":"2021","journal-title":"Viruses"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1126\/science.1227919","article-title":"Decoding human cytomegalovirus","volume":"338","author":"Stern-Ginossar","year":"2012","journal-title":"Science"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2020.02104","article-title":"Functional profile of human cytomegalovirus genes and their associated diseases: A review","volume":"11","author":"Ye","year":"2020","journal-title":"Front Microbiol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01155","article-title":"Subversion of immune response by human cytomegalovirus","volume":"10","author":"Patro","year":"2019","journal-title":"Front Immunol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1091\/mbc.12.6.1737","article-title":"The human cytomegalovirus Us28 protein is located in endocytic vesicles and undergoes constitutive endocytosis and recycling","volume":"12","author":"Fraile-Ramos","year":"2001","journal-title":"Mol Biol Cell"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.01754-17","article-title":"Latency-associated expression of human cytomegalovirus Us28 attenuates cell signaling pathways to maintain latent infection","volume":"8","author":"Krishna","year":"2017","journal-title":"mBio"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/s0014-5793(98)01551-8","article-title":"Selective recognition of the membrane-bound Cx3c chemokine, fractalkine, by the human cytomegalovirus-encoded broad-spectrum receptor Us28","volume":"441","author":"Kledal","year":"1998","journal-title":"FEBS Lett"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2004.07.076","article-title":"Hcmv-encoded chemokine receptor Us28 employs multiple routes for internalization","volume":"322","author":"Droese","year":"2004","journal-title":"Biochem Biophys Res Commun"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0854.2003.00079.x","article-title":"Endocytosis of the viral chemokine receptor Us28 does not require beta-arrestins but is dependent on the clathrin-mediated pathway","volume":"4","author":"Fraile-Ramos","year":"2003","journal-title":"Traffic"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3390\/v10080445","article-title":"Us28: Hcmv's Swiss army knife","volume":"10","author":"Krishna","year":"2018","journal-title":"Viruses"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.add1168","article-title":"Cytomegalovirus Us28 regulates cellular Epha2 to maintain viral latency","volume":"8","author":"Wass","year":"2022","journal-title":"Sci Adv"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.02574-19","article-title":"Interferon-responsive genes are targeted during the establishment of human cytomegalovirus latency","volume":"10","author":"Elder","year":"2019","journal-title":"mBio"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaa5026","article-title":"Structural biology. structural basis for chemokine recognition and activation of a viral G protein-coupled receptor","volume":"347","author":"Burg","year":"2015","journal-title":"Science"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.35850","article-title":"Viral gpcr Us28 can signal in response to chemokine agonists of nearly unlimited structural degeneracy","volume":"7","author":"Miles","year":"2018","journal-title":"Elife"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abl5442","article-title":"Atypical structural snapshots of human cytomegalovirus gpcr interactions with host G proteins","volume":"8","author":"Tsutsumi","year":"2022","journal-title":"Sci Adv"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-pharmtox-032112-135923","article-title":"Structure-function of the G protein-coupled receptor superfamily","volume":"53","author":"Katritch","year":"2013","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1146\/annurev-biochem-060614-033910","article-title":"The molecular basis of G protein-coupled receptor activation","volume":"87","author":"Weis","year":"2018","journal-title":"Annu Rev Biochem"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9258(19)61936-8","article-title":"Human cytomegalovirus open reading frame Us28 encodes a functional beta chemokine receptor","volume":"269","author":"Gao","year":"1994","journal-title":"J Biol Chem"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1006\/bbrc.1995.1814","article-title":"The cytomegalovirus Us28 protein binds multiple cc chemokines with high affinity","volume":"211","author":"Kuhn","year":"1995","journal-title":"Biochem Biophys Res Commun"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M407536200","article-title":"Cc and Cx3c chemokines differentially interact with the n terminus of the human cytomegalovirus-encoded Us28 receptor","volume":"280","author":"Casarosa","year":"2005","journal-title":"J Biol Chem"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M008965200","article-title":"Constitutive signaling of the human cytomegalovirus-encoded chemokine receptor Us28","volume":"276","author":"Casarosa","year":"2001","journal-title":"J Biol Chem"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/j.virol.2004.04.027","article-title":"Similar activation of signal transduction pathways by the herpesvirus-encoded chemokine receptors Us28 and Orf74","volume":"325","author":"McLean","year":"2004","journal-title":"Virology"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0854.2002.030307.x","article-title":"Localization of hcmv Ul33 and Us27 in endocytic compartments and viral membranes","volume":"3","author":"Fraile-Ramos","year":"2002","journal-title":"Traffic"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M303219200","article-title":"G-Protein-Coupled receptor (Gpcr) kinase phosphorylation and beta-arrestin recruitment regulate the constitutive signaling activity of the human cytomegalovirus Us28 gpcr","volume":"278","author":"Miller","year":"2003","journal-title":"J Biol Chem"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1124\/pharmrev.120.000186","article-title":"Viral G protein-coupled receptors: Attractive targets for herpesvirus-associated diseases","volume":"73","author":"De Groof","year":"2021","journal-title":"Pharmacol Rev"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M210033200","article-title":"Identification of the first nonpeptidergic inverse agonist for a constitutively active viral-encoded G protein-coupled receptor","volume":"278","author":"Casarosa","year":"2003","journal-title":"J Biol Chem"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.273.25.15687","article-title":"Identification and characterization of small molecule functional antagonists of the Ccr1 chemokine receptor","volume":"273","author":"Hesselgesser","year":"1998","journal-title":"J Biol Chem"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1111\/cbdd.12848","article-title":"Structure-based discovery of novel Us28 small molecule ligands with different modes of action","volume":"89","author":"Luckmann","year":"2017","journal-title":"Chem Biol Drug Des"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2018.05.053","article-title":"Ligand-selective small molecule modulators of the constitutively active vgpcr Us28","volume":"155","author":"Amarandi","year":"2018","journal-title":"Eur J Med Chem"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-018-0255-7","article-title":"The constitutive activity of the virally encoded chemokine receptor Us28 accelerates glioblastoma growth","volume":"37","author":"Heukers","year":"2018","journal-title":"Oncogene"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1021\/acs.molpharmaceut.9b00360","article-title":"Nanobody-targeted photodynamic therapy selectively kills viral gpcr-expressing glioblastoma cells","volume":"16","author":"De Groof","year":"2019","journal-title":"Mol Pharm"},{"key":"B51","doi-asserted-by":"publisher","first-page":"4436","DOI":"10.1038\/s41467-021-24608-5","article-title":"Targeting the latent human cytomegalovirus reservoir for T-Cell-Mediated killing with virus-specific nanobodies","volume":"12","author":"De Groof","year":"2021","journal-title":"Nat Commun"},{"key":"B52","doi-asserted-by":"publisher","first-page":"4357","DOI":"10.1038\/s41467-021-24574-y","article-title":"Selective targeting of ligand-dependent and -independent signaling by gpcr conformation-specific anti-Us28 intrabodies","volume":"12","author":"De Groof","year":"2021","journal-title":"Nat Commun"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1509392112","article-title":"Rationally designed chemokine-based toxin targeting the viral G protein-coupled receptor Us28 potently inhibits cytomegalovirus infection in vivo","volume":"112","author":"Spiess","year":"2015","journal-title":"Proc Natl Acad Sci U.S.A."},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/4069260","article-title":"Novel chemokine-based immunotoxins for potent and selective targeting of cytomegalovirus infected cells","volume":"2017","author":"Spiess","year":"2017","journal-title":"J Immunol Res"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms14321","article-title":"Targeting the latent cytomegalovirus reservoir with an antiviral fusion toxin protein","volume":"8","author":"Krishna","year":"2017","journal-title":"Nat Commun"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2015.00963","article-title":"Pseudomonas exotoxin a: Optimized by evolution for effective killing","volume":"6","author":"Michalska","year":"2015","journal-title":"Front Microbiol"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1016\/j.healun.2020.01.1310","article-title":"Targeting latent human cytomegalovirus (Cmv) with a novel fusion toxin protein during ex vivo lung perfusion","volume":"39","author":"Ribeiro","year":"2020","journal-title":"J Heart Lung Transpl"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1016\/j.healun.2021.10.010","article-title":"Ex vivo treatment of cytomegalovirus in human donor lungs using a novel chemokine-based immunotoxin","volume":"41","author":"Ribeiro","year":"2022","journal-title":"J Heart Lung Transplant"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1006\/jmbi.1995.0152","article-title":"Molecular phylogeny and evolutionary timescale for the family of mammalian herpesviruses","volume":"247","author":"McGeoch","year":"1995","journal-title":"J Mol Biol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.03406-12","article-title":"Identification of common mechanisms by which human and mouse cytomegalovirus seven-transmembrane receptor homologues contribute to in vivo phenotypes in a mouse model","volume":"87","author":"Farrell","year":"2013","journal-title":"J Virol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.02113-10","article-title":"Partial functional complementation between human and mouse cytomegalovirus chemokine receptor homologues","volume":"85","author":"Farrell","year":"2011","journal-title":"J Virol"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1099\/jgv.0.001230","article-title":"Cytomegalovirus host entry and spread","volume":"100","author":"Farrell","year":"2019","journal-title":"J Gen Virol"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1038\/nrd.2017.178","article-title":"Trends in gpcr drug discovery: New agents, targets and indications","volume":"16","author":"Hauser","year":"2017","journal-title":"Nat Rev Drug Discovery"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.73.6.4806-4812.1999","article-title":"Quantitative analysis of latent human cytomegalovirus","volume":"73","author":"Slobedman","year":"1999","journal-title":"J Virol"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-virology-110615-042422","article-title":"Human cytomegalovirus latency: Approaching the Gordian knot","volume":"3","author":"Goodrum","year":"2016","journal-title":"Annu Rev Virol"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1710522114","article-title":"Transcriptome-wide characterization of human cytomegalovirus in natural infection and experimental latency","volume":"114","author":"Cheng","year":"2017","journal-title":"Proc Natl Acad Sci U.S.A."},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00578-15","article-title":"High-throughput analysis of human cytomegalovirus genome diversity highlights the widespread occurrence of gene-disrupting mutations and pervasive recombination","volume":"89","author":"Sijmons","year":"2015","journal-title":"J Virol"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1099\/vir.0.79888-0","article-title":"Genetic content of wild-type human cytomegalovirus","volume":"85","author":"Dolan","year":"2004","journal-title":"J Gen Virol"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1010355","article-title":"The non-elr cxc chemokine encoded by human cytomegalovirus Ul146 genotype 5 contains a c-terminal beta-hairpin and induces neutrophil migration as a selective Cxcr2 agonist","volume":"18","author":"Berg","year":"2022","journal-title":"PloS Pathog"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1400291","article-title":"Novel human cytomegalovirus viral chemokines, vcxcl-1s, display functional selectivity for neutrophil signaling and function","volume":"195","author":"Heo","year":"2015","journal-title":"J Immunol"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1086\/344238","article-title":"Polymorphisms of the cytomegalovirus (Cmv)-encoded tumor necrosis factor-alpha and beta-chemokine receptors in congenital cmv disease","volume":"186","author":"Arav-Boger","year":"2002","journal-title":"J Infect Dis"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1007\/s11262-005-0054-4","article-title":"Comparative sequence analysis of Us28 gene of human cytomegalovirus strains isolated from hiv-positive patients","volume":"33","author":"Goffard","year":"2006","journal-title":"Virus Genes"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1128\/Spectrum.00020-21","article-title":"Sequencing directly from clinical specimens reveals genetic variations in hcmv-encoded chemokine receptor Us28 that may influence antibody levels and interactions with human chemokines","volume":"9","author":"Waters","year":"2021","journal-title":"Microbiol Spectr"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1007\/s00430-019-00581-1","article-title":"Hcmv latency: What regulates the regulators","volume":"208","author":"Elder","year":"2019","journal-title":"Med Microbiol Immunol"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1084\/jem.179.1.185","article-title":"The conditions of primary infection define the load of latent viral genome in organs and the risk of recurrent cytomegalovirus disease","volume":"179","author":"Reddehase","year":"1994","journal-title":"J Exp Med"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.72.3.1797-1804.1998","article-title":"Preemptive Cd8 T-cell immunotherapy of acute cytomegalovirus infection prevents lethal disease, limits the burden of latent viral genomes, and reduces the risk of virus recurrence","volume":"72","author":"Steffens","year":"1998","journal-title":"J Virol"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.02442-10","article-title":"Human cytomegalovirus Pus27 G protein-coupled receptor homologue is required for efficient spread by the extracellular route but not for direct cell-to-Cell spread","volume":"85","author":"O'Connor","year":"2011","journal-title":"J Virol"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.11.4721-4732.2005","article-title":"Maraviroc (Uk-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor Ccr5 with broad-spectrum anti-human immunodeficiency virus type 1 activity","volume":"49","author":"Dorr","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-08-174946","article-title":"Plerixafor and G-csf versus placebo and G-csf to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma","volume":"113","author":"DiPersio","year":"2009","journal-title":"Blood"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.20.7209","article-title":"Phase iii prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-hodgkin's lymphoma","volume":"27","author":"DiPersio","year":"2009","journal-title":"J Clin Oncol"},{"key":"B81","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1038\/s42003-021-02070-9","article-title":"Biased action of the Cxcr4-targeting drug plerixafor is essential for its superior hematopoietic stem cell mobilization","volume":"4","author":"Jorgensen","year":"2021","journal-title":"Commun Biol"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.2217\/imt.14.94","article-title":"Mogamulizumab and the treatment of Ccr4-positive T-cell lymphomas","volume":"6","author":"Remer","year":"2014","journal-title":"Immunotherapy"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1135280\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,13]],"date-time":"2023-02-13T06:56:54Z","timestamp":1676271414000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1135280\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,13]]},"references-count":82,"alternative-id":["10.3389\/fimmu.2023.1135280"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2023.1135280","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,13]]},"article-number":"1135280"}}